Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026
Pipeline Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease pharminent August 11, 2026
Pipeline BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication pharminent August 10, 2026
Pipeline Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts pharminent August 5, 2026
Pipeline AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist pharminent July 10, 2026
Pipeline AlzeCure enters collaboration agreement with QuantumCell ApS for NeuroRestore project pharminent July 1, 2026
Pipeline Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? pharminent June 5, 2026
Pipeline Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update pharminent May 20, 2026
Pipeline Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimism pharminent May 14, 2026
Pipeline AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio pharminent April 30, 2026
Pipeline Rejuvenate crowdfunds development of gene therapy for aging, chronic diseases pharminent April 27, 2026
Pipeline Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer pharminent April 24, 2026
Pipeline Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’ pharminent April 23, 2026
Pipeline Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine pharminent April 21, 2026
Pipeline Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway pharminent April 8, 2026
Business Pipeline How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup pharminent March 24, 2026
